Liver News and Research

RSS

Long-term use of statins reduces colorectal cancer risk

A systematic review of the medical literature supports the hypothesis that statins, cholesterol-lowering drugs used to prevent cardiac problems, are associated with reduced risk of colon and rectal cancers.

19 Oct 2010

Study investigates effectiveness of potential treatment for Non-alcoholic steatohepatitis

Estimates of the prevalence of liver disease suggest that one‐third of the United States population has non‐alcoholic fatty liver disease (NAFLD). NAFLD is now the most common cause for elevated liver function tests in the United States, a trend related to the obesity epidemic in this country. Non-alcoholic steatohepatitis (NASH), the progressive form of NAFLD, can lead to cirrhosis and all its complications.

19 Oct 2010

Micronics to advance PanNAT system for molecular diagnosis of infectious pathogens

Micronics, Inc., a development-stage company, today announced that the Department of Defense has awarded the company an Applied Research and Technology Development Award under the U.S. Army Medical Research and Materiel Command's Polytrauma and Blast Injury project for advancement of its PanNAT system for point-of-care molecular diagnosis of infectious pathogens.

19 Oct 2010

Medifocus receives two patents to expand IP portfolio

Medifocus, Inc. is pleased to announce that it has recently received notice of allowances for two additional international patents to expand its extensive Intellectual Properties (IP) portfolio in addition to the patents Medifocus has exclusively licensed from the Massachusetts Institute of Technology (MIT).

19 Oct 2010

Researchers report breakthrough studies in liver cell transplantation

Two research teams from the Okayama University Graduate School of Medicine (Okayama, Japan) have reported breakthrough studies in liver cell transplantation.

19 Oct 2010

BARACLUDE sNDA receives FDA approval for treatment of CHB patients with decompensated liver disease

Bristol-Myers Squibb Company announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) of BARACLUDE for the treatment of chronic hepatitis B (CHB) in adult patients with decompensated liver disease.

18 Oct 2010

Statins reduce risk of colon and rectal cancers: Study

A systematic review of the medical literature supports the hypothesis that statins, cholesterol‐lowering drugs used to prevent cardiac problems, are associated with reduced risk of colon and rectal cancers. A comprehensive analysis by investigators at the University of Michigan at Ann Arbor, included 22 scientific studies with more than 2.5 million combined participants.

18 Oct 2010

EC grants orphan drug designation to S*BIO's SB1518 for treatment of myelofibrosis

S*BIO Pte Ltd today announced that the European Commission (EC) has granted orphan drug designation to SB1518, its potent and orally active JAK2 inhibitor for the treatment of primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and post-essential thrombocythemia myelofibrosis (PET-MF). SB1518 has also received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of the same disorder.

18 Oct 2010

UK College of Medicine celebrates 50th anniversary

The year 2010 marks a significant date in the history of the University of Kentucky College of Medicine as it celebrates its 50th anniversary. The festivities culminate on Oct. 15 with the Signature Event, held at the Keeneland Sales Pavilion. This year commemorates individuals who have been a part of the accomplishments of the past five decades and for those who will be a part of its bright future.

18 Oct 2010

Cempra to present data on solithromycin, TAKSTA at 48th Annual Meeting in Vancouver

Cempra Pharmaceuticals today announced poster presentations on its novel fluoroketolide antibiotic, solithromycin (CEM-101), and the Company's proprietary front-loading oral dosing regimen of sodium fusidate, TAKSTA (CEM-102) at the 48th Annual Meeting of the Infectious Diseases Society of America in Vancouver, British Columbia.

18 Oct 2010

Royal Cornwall Hospital receives grant to study Hepatitis E

Researchers from the Royal Cornwall Hospital in Truro have received a grant of -337,000 to carry out a two-year study with partners in Glasgow and Norwich into a rare form of Hepatitis - Hepatitis E. The grant has come from the Chief Scientist's Office for Scotland and will be divided between the three centres taking part in the study.

18 Oct 2010

New development of genetic tool to speed discovery of novel genes involved in cancer

Researchers have developed a genetic tool in mice to speed the discovery of novel genes involved in cancer. The system - called PiggyBac - has already been used by the team to identify novel candidate cancer-causing genes.

15 Oct 2010

Experts use multi-disciplinary approach to provide innovative care for children

Liver tumors affect more than 300 children in the United States each year and management of these children requires coordinated comprehensive care from experts in many disciplines. To answer this problem, Texas Children's Hospital and Baylor College of Medicine announced today the formation of a new Liver Tumor Center that brings together renowned specialists in all aspects of liver cancer who will utilize a multi-disciplinary approach to provide the most comprehensive and innovative care for children afflicted with these diseases.

15 Oct 2010

MRI-guided laser ablation offers way to kill tumors

Physicians at Mayo Clinic's Florida campus are among the first in the nation to use a technique known as MRI-guided laser ablation to heat up and destroy kidney and liver tumors. So far, five patients have been successfully treated meaning no visible tumors remained after the procedure.

15 Oct 2010

FibroGen announces initiation of FG-3019 phase 2 study for reversing liver fibrosis

FibroGen, Inc. today announced initiation of a phase 2 study to compare the efficacy of FG-3019, a human monoclonal antibody against connective tissue growth factor (CTGF), with placebo in reversing liver fibrosis (scarring of the liver) due to chronic infection with hepatitis B virus (HBV).

15 Oct 2010

Acetadote Injection is now commercially available in Australia

Cumberland Pharmaceuticals Inc. and Phebra Pty Ltd. today announced that Acetadote (acetylcysteine) Injection, an injectable product used to treat acetaminophen (paracetamol) overdose, is now commercially available in the Australian market. Phebra Pty Ltd., an Australian-based specialty pharmaceutical company, has an exclusive license from U.S.-based Cumberland Pharmaceuticals to market and distribute the product in Australia.

15 Oct 2010

Study confirms long term survival benefit of ELAD bioartificial liver support system in Chinese ACLF patients

Vital Therapies, Inc., today announced that a poster is being presented at the American Association for the Study of Liver Diseases (AASLD) meeting in Boston on Tuesday, November 2nd. It confirms that previously reported findings of improved transplant free survival (TFS) in Chinese subjects with acute-on-chronic liver failure (ACLF) treated with the ELAD® bioartificial liver support system are maintained for up to three years.

14 Oct 2010

Humanitas Clinic treats first cancer patient using TrueBeam technology

A 54-year-old head & neck cancer patient has become the first person in Italy to be treated using a revolutionary new linear accelerator that can deliver radiotherapy twice as fast as conventional therapy machines. The Humanitas Clinic in Rozzano-Milan carried out the treatment last week, becoming only the third hospital in Europe to begin clinical treatments using TrueBeam from Varian Medical Systems.

13 Oct 2010

Bariatric surgery reduces healthcare costs for morbidly obese diabetics

New data presented today at Obesity 2010, the 28th annual scientific meeting of The Obesity Society, find that bariatric surgery is associated with reduced healthcare costs for diabetes patients who are morbidly obese.

13 Oct 2010

Beta-Pro expands operations to meet increasing demand in $2 billion hepatocyte market

Beta-Pro LLC, announced today that it has expanded its operations to accommodate increasing demands from pharmaceutical drug discovery and research institutes in the $2 billion hepatocyte market. The human cellular sciences company now manages extensive laboratory facilities in the University of Virginia Research Park in Charlottesville, Virginia.

13 Oct 2010

Liver News and Research

Long-term use of statins reduces colorectal cancer risk

Study investigates effectiveness of potential treatment for Non-alcoholic steatohepatitis

Micronics to advance PanNAT system for molecular diagnosis of infectious pathogens

Medifocus receives two patents to expand IP portfolio

Researchers report breakthrough studies in liver cell transplantation

BARACLUDE sNDA receives FDA approval for treatment of CHB patients with decompensated liver disease

Statins reduce risk of colon and rectal cancers: Study

EC grants orphan drug designation to S*BIO's SB1518 for treatment of myelofibrosis

UK College of Medicine celebrates 50th anniversary

Cempra to present data on solithromycin, TAKSTA at 48th Annual Meeting in Vancouver

Royal Cornwall Hospital receives grant to study Hepatitis E

New development of genetic tool to speed discovery of novel genes involved in cancer

Experts use multi-disciplinary approach to provide innovative care for children

MRI-guided laser ablation offers way to kill tumors

FibroGen announces initiation of FG-3019 phase 2 study for reversing liver fibrosis

Acetadote Injection is now commercially available in Australia

Study confirms long term survival benefit of ELAD bioartificial liver support system in Chinese ACLF patients

Humanitas Clinic treats first cancer patient using TrueBeam technology

Bariatric surgery reduces healthcare costs for morbidly obese diabetics

Beta-Pro expands operations to meet increasing demand in $2 billion hepatocyte market

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News